Company intelligence / Profile preview

ReviveMed Technologies

Cambridge, MA, USA

Ownership: Private
Development stage: Other

Overview

ReviveMed operates a patented AI-based large-scale metabolomics platform that creates digital metabolic twins to predict treatment response (notably to cancer immunotherapy), assess metabolic health and chronic disease risk, and identify novel drug targets; current activities are platform and biomarker/target discovery focused rather than running proprietary therapeutic assets in clinical trials.[2][3]

Therapeutic areas: EndocrinologyCardiovascularGastroenterologyMetabolic DisordersOncology
Modalities: Small moleculeBiologicDeviceNon-pharmacological therapy
Industry: Metabolite Diagnostics

Partnerships

Pharmaceutical and biotech companies using the platform for drug target discovery, biomarker development, and clinical trial optimization (partners not named publicly).[1][2][3]

Beyond the preview

Go deeper on ReviveMed Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReviveMed Technologies.

Explore the full profile